231 related articles for article (PubMed ID: 9266515)
1. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Mortensen SA; Leth A; Agner E; Rohde M
Mol Aspects Med; 1997; 18 Suppl():S137-44. PubMed ID: 9266515
[TBL] [Abstract][Full Text] [Related]
2. The effect of pravastatin and atorvastatin on coenzyme Q10.
Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ
Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481
[TBL] [Abstract][Full Text] [Related]
3. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Strauss WE; Lapsley D; Gaziano JM
Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
[TBL] [Abstract][Full Text] [Related]
5. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Passi S; Stancato A; Aleo E; Dmitrieva A; Littarru GP
Biofactors; 2003; 18(1-4):113-24. PubMed ID: 14695926
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
Kostis JB; Rosen RC; Wilson AC
J Clin Pharmacol; 1994 Oct; 34(10):989-96. PubMed ID: 7836550
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
Miyake Y; Shouzu A; Nishikawa M; Yonemoto T; Shimizu H; Omoto S; Hayakawa T; Inada M
Arzneimittelforschung; 1999 Apr; 49(4):324-9. PubMed ID: 10337451
[TBL] [Abstract][Full Text] [Related]
9. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
Ghirlanda G; Oradei A; Manto A; Lippa S; Uccioli L; Caputo S; Greco AV; Littarru GP
J Clin Pharmacol; 1993 Mar; 33(3):226-9. PubMed ID: 8463436
[TBL] [Abstract][Full Text] [Related]
10. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Glorioso N; Troffa C; Filigheddu F; Dettori F; Soro A; Parpaglia PP; Collatina S; Pahor M
Hypertension; 1999 Dec; 34(6):1281-6. PubMed ID: 10601131
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects.
Ehrenberg BL; Lamon-Fava S; Corbett KE; McNamara JR; Dallal GE; Schaefer EJ
Sleep; 1999 Feb; 22(1):117-21. PubMed ID: 9989373
[TBL] [Abstract][Full Text] [Related]
12. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.
Laaksonen R; Ojala JP; Tikkanen MJ; Himberg JJ
Eur J Clin Pharmacol; 1994; 46(4):313-7. PubMed ID: 7957515
[TBL] [Abstract][Full Text] [Related]
13. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
Human JA; Ubbink JB; Jerling JJ; Delport R; Vermaak WJ; Vorster HH; Lagendijk J; Potgieter HC
Clin Chim Acta; 1997 Jul; 263(1):67-77. PubMed ID: 9247729
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Jacob BG; Möhrle W; Richter WO; Schwandt P
Eur J Clin Pharmacol; 1992; 42(4):353-8. PubMed ID: 1516599
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Ogawa N; Goto Y
Atherosclerosis; 2002 Jun; 162(2):373-9. PubMed ID: 11996957
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
Steinhagen-Thiessen E
Cardiology; 1994; 85(3-4):244-54. PubMed ID: 7987882
[TBL] [Abstract][Full Text] [Related]
20. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.
Am J Cardiol; 1993 Apr; 71(10):810-5. PubMed ID: 8456759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
